Related Experiment Video
Updated: May 4, 2026
07:16
Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
14.1K
Sugammadex: a novel selective relaxant binding agent.
Mohamed Naguib1, Sorin J Brull
1Department of Anesthesiology and Pain Medicine, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, TX 77003, USA. naguib@mdanderson.org.
Expert Review of Clinical Pharmacology
|January 16, 2014
Summary
Sugammadex, a selective relaxant binding agent, effectively reverses neuromuscular blockade from rocuronium and vecuronium. It offers flexibility in anesthesia without anticholinergic side effects, though hypersensitivity concerns require further study.
Area of Science:
- Anesthesiology
- Pharmacology
- Drug Development
Background:
- Sugammadex is a novel selective relaxant binding agent.
- It forms stable complexes with steroidal neuromuscular blocking agents like rocuronium and vecuronium.
- Existing reversal agents for neuromuscular blockade have limitations and potential adverse effects.
Purpose of the Study:
- To evaluate the efficacy and safety of sugammadex in reversing neuromuscular blockade.
- To assess the pharmacokinetic profile and recommended dosing of sugammadex.
- To compare adverse effects of sugammadex with placebo and traditional reversal agents.
Main Methods:
- Phase I-III clinical trials were conducted.
- Sugammadex efficacy was assessed across various levels of neuromuscular blockade.
- Safety and adverse events were monitored and compared to placebo.
Main Results:
- Sugammadex demonstrated effective reversal of neuromuscular blockade, including profound blockade induced by rocuronium.
- The drug exhibits rapid clearance from organs.
- Recommended doses range from 2 to 16 mg/kg based on blockade level.
- Common adverse effects were comparable to placebo, including anesthetic complications and cough.
Conclusions:
- Sugammadex provides a flexible and effective option for reversing neuromuscular blockade.
- It eliminates the need for anticholinergic drugs, reducing associated adverse effects.
- While generally well-tolerated, hypersensitivity reactions warrant ongoing safety monitoring.
Related Concept Videos
01:31Skeletal Muscle Relaxants: Therapeutic Uses
1.2K
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.2K
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
981
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
981
01:28Classification of Skeletal Muscle Relaxants
3.6K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
3.6K
01:21Skeletal Muscle Relaxants: Adverse Effects
1.2K
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
1.2K
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
2.2K
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
2.2K
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
3.6K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
3.6K